In Law360, LSRC Attorneys Examine HHS Announcement Barring FDA from Requiring Premarket Review for Laboratory-Developed Tests

In The News
September 2, 2020

Life sciences regulatory & compliance partner and chair Greg Levine, counsel Beth Weinman and associate Joshua Oyster (all of Washington, D.C.) co-authored a Law360 article that examines the likely impact, both during and after the COVID-19 pandemic, of a recent U.S. Department of Health and Human Services announcement preventing FDA from insisting on premarket review for laboratory-developed tests absent notice and comment rulemaking.